2013
DOI: 10.1089/vbz.2012.1007
|View full text |Cite
|
Sign up to set email alerts
|

Clinician Assessment forCoxiella burnetiiInfection in Hospitalized Patients with Potentially Compatible Illnesses During Q Fever Outbreaks and Following a Health Alert, Montana, 2011

Abstract: Clinicians should assess for Q fever risk factors and consider the diagnosis in patients hospitalized with Q fever-compatible illnesses when the etiology of illness is unknown. Work is warranted to evaluate the effectiveness of current healthcare alert practices for zoonotic diseases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…The treatment plan for chronic Q fever involves an 18-month-long combined antibiotic therapy and currently, there is no Q fever vaccine licensed in the U.S., presenting challenges in both treating and preventing the disease. Q fever has emerged as a significant public health concern worldwide [2][3][4][5][6][7][8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…The treatment plan for chronic Q fever involves an 18-month-long combined antibiotic therapy and currently, there is no Q fever vaccine licensed in the U.S., presenting challenges in both treating and preventing the disease. Q fever has emerged as a significant public health concern worldwide [2][3][4][5][6][7][8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…The treatment plan for chronic Q fever involves an 18-month-long combined antibiotic therapy and currently, there is no Q fever vaccine licensed in the U.S., presenting challenges in both treating and preventing the disease. Q fever has emerged as a significant public health concern worldwide ( Lyytikainen et al., 1998 ; Amitai et al., 2010 ; Porter et al., 2011 ; Nett et al., 2013 ; White et al., 2013 ; Angelakis et al., 2014 ; Bjork et al., 2014 ; Eldin et al., 2014 ; Alonso et al., 2015 ).…”
Section: Introductionmentioning
confidence: 99%
“…Further, the only vaccine available for humans is licensed exclusively in Australia due to reactivity issues [10]. Between 2007 and 2010, the Netherlands experienced a large Q fever outbreak with more than 40,000 individuals infected [11], with smaller outbreaks occurring in the US [12][13][14], Spain [15], Australia [15], Japan [16] and Israel [17]. These outbreaks exemplify how expansive C. burnetii is globally, but the scarcity of prevention and treatment options is due to our lack of understanding of C. burnetii pathogenesis.…”
Section: Introductionmentioning
confidence: 99%